TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11032403
Drug: Twice-a-day IFN-beta
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-a-day IFN-beta injection
Study: 3904894
Drug: Ioxaglate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (200 mg iodine/ml)
Study: 30287610
Drug: Medication reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reduction (stopping one antihypertensive medication) with optional self-monitoring
Study: 25046730
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of melatonin in soft gel capsules
Study: 25046730
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of melatonin powder
Study: 20362711
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab application during PCI
Study: 20362711
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of abciximab for 12 hours post-PCI
Study: 16699827
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and taurine pills
Study: 12816784
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d iron supplement (ferrous sulfate)
Study: 9097068
Drug: 8-week depression
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week depression treatment trial
Study: 9097068
Drug: Additional courses
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional courses of antidepressant therapy
Study: 8200383
Drug: Adjuvant progestagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant progestagen therapy
Study: 17468819
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and intravenous antimicrobial prophylaxis
Study: 29654027
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic prophylaxis alone
Study: 27741344
Drug: Dapsone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone gel, 7.5% (3 formulations: DAP-11078, DAP-11079, DAP-11080), applied once daily
Study: 27741344
Drug: Dapsone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone gel, 5%, applied twice-daily
Study: 27741344
Drug: All dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dapsone formulations (7.5% and 5%)
Study: 24943000
Drug: Empagliflozin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (both doses pooled)
Study: 23031516
Drug: Cu supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cu supplementation (15 mg Cu sulphate/kg dry matter)
Study: 18448618
Drug: Intranasal dose
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dose of 10(7) fluorescent focus units (FFU) of a live attenuated influenza virus vaccine (CAIV‐T)
Study: 18448618
Drug: Commercial inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial inactivated influenza virus vaccine
Study: 11864918
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone treatment
Study: 11864918
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hormone treatment)
Study: 10408993
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of beta lactam antibiotics and erythromycin
Study: 10408993
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of clindamycin, tetracycline, trimethoprim/sulfamethoxazole, and ciprofloxacin
Study: 10408993
Drug: Hospitalized patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized patients receiving multiple drugs
Study: 7749974
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg), Diphenhydramine (25 mg), Chlorpheniramine (4 mg)
Study: 7749974
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg) vs Chlorpheniramine (4 mg)
Study: 2210597
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg isosorbide dinitrate in sustained-release form
Study: 6171572
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (HLI) at a daily dose of 10(6) units applied by contraceptive pessary technique for 14 days in patients with viral alterations and 21 days in those with changed cytologic findings.
Study: 6205924
Drug: Propafenon (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenon (300 mg three times daily)
Study: 6205924
Drug: Dihydroquinidine Chloride
Normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroquinidine Chloride (300 mg six times daily)
Study: 29277963
Drug: Reactive gel
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive gel mattress
Study: 22935526
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose 600 mg
Study: 22935526
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose 300 mg
Study: 17953950
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral nimesulide
Study: 17117562
Drug: Synthetic auricular
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic auricular point therapy (blood‐letting on the ear back, point injection of own blood, pricking ear point)
Study: 9553237
Drug: Lidocaine 60
Normalized name: Gabapentin;Lidocaine 600 MG; 5% Multiple Routes Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 60 mg
Study: 15333400
Drug: Ropivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 15 mg
Study: 12594142
Drug: Levobupivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 10 mg
Study: 10668837
Drug: Sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nifedipine
Study: 1422320
Drug: Ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (600 mg/day)
Study: 4074607
Drug: Conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional metoprolol 200 mg
Study: 4074607
Drug: Long-acting metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting metoprolol 200 mg
Study: 31420920
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (dual COX inhibition)
Study: 31420920
Drug: Standard low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard low-dose aspirin (selective COX-1 inhibition)
Study: 28204882
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 50 µg
Study: 22640229
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 25 µg
Study: 15942186
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment twice a year at 6-month intervals
Study: 15942186
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment 3 times a year within 1 week
Study: 15942186
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment 8 times per year during semesters with 1-month intervals
Study: 15942186
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment once a year
Study: 12952112
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride (180 mg)
Study: 12589354
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride (5 mg)
Study: 8991237
Drug: Combined yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined yellow fever and measles vaccines
Study: 8991237
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine administered separately
Study: 8991237
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine administered separately
Study: 29948103
Drug: Overnight treatment
Normalized name: Dermarest Psoriasis Overnight Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight treatment with the occlusive intensive patch (OIP) containing Allium cepa extract and allantoin for 12-24 weeks
Study: 29948103
Drug: Overnight treatment
Normalized name: Dermarest Psoriasis Overnight Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight treatment with the occlusive intensive patch (OIP)
Study: 26329980
Drug: Atomoxetine (40-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40-100 mg/day)
Study: 18193377
Drug: Phytosterol enriched
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol enriched drinkable yogurt (1.6 g of free sterol equivalents)
Study: 11140432
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) administered via dry powder and metered-dose inhalers
Study: 8872851
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with felodipine
Study: 8872851
Drug: Low-dose felodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose felodipine
Study: 8872851
Drug: High-dose felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose felodipine plus additional drugs
Study: 1511150
Drug: Monthly performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly performance overviews comparing individual doctors to peers
Study: 6595452
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (10,000 IU daily)
Study: 30554409
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum levels of NOx over 70 µmol/L
Study: 30554409
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum levels of NOx over 70 µmol/L in men
Study: 25541919
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg every 6 hours) intravenously for fifteen days
Study: 19947262
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Shenshu (BL 23), Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6) for 12 weeks
Study: 19947262
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Polyene Phosphatidylcholine Capsules for 12 weeks
Study: 12017408
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg once daily for 5 days
Study: 15277269
Drug: Study recommendations
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study recommendations for boost radiation treatment
Study: 15277269
Drug: Stated policy
Normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stated policy for boost radiation treatment
Study: 11455677
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated formulation containing 90 mg peppermint oil and 50 mg caraway oil (test)
Study: 11455677
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation containing 36 mg peppermint oil and 20 mg caraway oil (reference)
Study: 11455677
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated formulation (test)
Study: 11455677
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation (reference)
Study: 9744605
Drug: Sublingual hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual hyoscyamine (0.125 mg/tablet, 2 tablets)
Study: 7799699
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium cromoglycate
Study: 30690687
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=1113)
Study: 9103468
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 2 min before endotoxin challenge
Study: 9103468
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 1 hour after endotoxin challenge
Study: 9103468
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 (rhIL-10) administered both before and after endotoxin challenge
Study: 28980166
Drug: Intermittent cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cefotaxime dosing regimens
Study: 28980166
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefotaxime at 100 mg·kg-1·day-1
Study: 24338947
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention (cognitive-behavioral therapy and/or psychopharmacology)
Study: 22569436
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg every other day)
Study: 15675576
Drug: Newer agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer agents (TS‐1, CPT‐11, docetaxel, paclitaxel)
Study: 7798503
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with streptokinase, recombinant tissue-type plasminogen activator, or anistreplase plus intravenous heparin (5,000 IU bolus followed by 1,000 U/h infusion)
Study: 6118380
Drug: Dextropropoxyphene preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene preparation (Doleron novum)
Study: 6118380
Drug: Codeine preparation
Normalized name: codeine / Erysimum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine preparation (Staralgin)
Study: 31767717
Drug: 3g oral
Normalized name: Fosfomycin Tromethamine 3g Oral granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g oral fosfomycin tromethamine every other day (QOD) for 3 doses and then every day (QD) for 7 doses
Study: 27860267
Drug: RN317 (s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RN317 (s.c. 3.0 mg/kg)
Study: 27860267
Drug: Bococizumab (s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bococizumab (s.c. 3.0 mg/kg)
Study: 27860267
Drug: Multiple-dose RN317
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose RN317 (s.c. 300 mg every 28 days; three doses)
Study: 24967824
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Tranexamic acid (TXA) postoperatively, diluted to 0.2% concentration, gargled or sprayed 5-6 times daily from postoperative day 5-10.
Study: 24967824
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Tranexamic acid (TXA) postoperatively
Study: 23110312
Drug: Fibermalt 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibermalt 45 g/d
Study: 23110312
Drug: Fibermalt 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibermalt 60 g/d
Study: 23110312
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/d)
Study: 21859366
Drug: Iron(III) polymaltose
Normalized name: Iron (III) oxide adipate
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III) polymaltose complex (Maltofer(®)) 100 mg iron twice daily for 90 days
Study: 21859366
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 100 mg iron twice daily for 90 days
Study: 15215110
Drug: BAL5788 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL5788 (750 mg)
Study: 15215110
Drug: BAL5788 (125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL5788 (125, 250, 500, 750, and 1,000 mg)
Study: 11521989
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (400 mg b.i.d.)
Study: 8168039
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF regimen (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Study: 8168039
Drug: DES-CMF (CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-CMF (CMF preceded by diethylstilbestrol 1 mg orally per day for 3 days)
Study: 31077751
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D tablet, 1000IU/day (N=180; 69 boys, 111 girls)
Study: 31077751
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D fortified milk consumption, 200 ml/day, 40IU/100 ml (N=189; 93 boys, 96 girls)
Study: 28865716
Drug: Risperidone maintenance
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone maintenance treatment for 1 year
Study: 28865716
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment length
Study: 25878120
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of imatinib combined with reduced-intensity chemotherapy (arm A)
Study: 25878120
Drug: Standard imatinib/hyperCVAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard imatinib/hyperCVAD therapy (arm B)
Study: 16877377
Drug: Daily 112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 112.5 IU recombinant FSH from cycle day 2-6 (Group A)
Study: 16877377
Drug: Daily 112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 112.5 IU recombinant FSH from cycle day 7-11 (Group B)
Study: 12508146
Drug: IC14 (anti-CD14
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (anti-CD14 antibody)
Study: 8829932
Drug: Inhalational anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational anaesthesia with nitrous oxide (induced with thiopentone 6 mg kg‐1, maintained with halothane 1% and nitrous oxide 66% in oxygen)
Study: 8829932
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol-alfentanil (induced with alfentanil 25 micrograms kg‐1 and propofol 2 mg kg‐1, maintained with alfentanil and propofol infusions)
Study: 2056774
Drug: Aclarubicin (ACR)
Normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclarubicin (ACR) 75 mg/m2 daily for 3 days plus cytosine arabinoside (ara‐C) 100 mg/m2 per day for 7 days
Study: 2056774
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 45 mg/m2/day for 3 days plus ara‐C for 7 days
Study: 6601847
Drug: sulfadimidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfadimidine (1 g four times daily for seven days)
Study: 6601847
Drug: tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetracycline (500 mg four times daily for seven days)
Study: 6601847
Drug: trimethoprim‐sulfamethoxazole (TMP‐SMZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim‐sulfamethoxazole (TMP‐SMZ; 160 mg of TMP and 800 mg of SMZ twice daily for seven days)
Study: 6601847
Drug: doxycycline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline (300 mg as a single dose)
Study: 6601847
Drug: TMP‐sulfametrole (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐sulfametrole (640 mg of TMP and 3,200 mg of sulfametrole once as a single dose)
Study: 30032464
Drug: Smartphone-based upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based upper airway exercises (15 min of daily gameplay)
Study: 30032464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 s of daily voice recording)
Study: 28115223
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Rotacaps/Rotahaler
Study: 28115223
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Diskus
Study: 28115223
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via either inhaler